Trial Profile
A Randomized Phase II Study of Ruxolitinib (NSC-752295) in Combination With BCR-ABL Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia (CML) Patients With Molecular Evidence of Disease
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 17 Nov 2023
Price :
$35
*
At a glance
- Drugs Bosutinib (Primary) ; Dasatinib (Primary) ; Imatinib (Primary) ; Nilotinib (Primary) ; Ruxolitinib (Primary)
- Indications Chronic myeloid leukaemia
- Focus Therapeutic Use
- 09 Nov 2023 Planned End Date changed from 1 Jan 2028 to 1 Jul 2028.
- 09 Nov 2023 Planned primary completion date changed from 1 Jan 2024 to 1 Jul 2024.
- 14 Dec 2022 Status changed from recruiting to active, no longer recruiting.